Ex vivo expansion of circulating tumour cells (CTCs).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 03 2023
06 03 2023
Historique:
received:
19
05
2022
accepted:
28
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
9
3
2023
Statut:
epublish
Résumé
Circulating tumour cells (CTCs) are a critical intermediate step in the process of cancer metastasis. The reliability of CTC isolation/purification has limited both the potential to report on metastatic progression and the development of CTCs as targets for therapeutic intervention. Here we report a new methodology, which optimises the culture conditions for CTCs using primary cancer cells as a model system. We exploited the known biology that CTCs thrive in hypoxic conditions, with their survival and proliferation being reliant on the activation of hypoxia-inducible factor 1 alpha (HIF-1α). We isolated epithelial-like and quasi-mesenchymal CTC phenotypes from the blood of a cancer patient and successfully cultured these cells for more than 8 weeks. The presence of CTC clusters was required to establish and maintain long-term cultures. This novel methodology for the long-term culture of CTCs will aid in the development of downstream applications, including CTC theranostics.
Identifiants
pubmed: 36879003
doi: 10.1038/s41598-023-30733-6
pii: 10.1038/s41598-023-30733-6
pmc: PMC9988863
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3704Informations de copyright
© 2023. The Author(s).
Références
Comp Biochem Physiol A Physiol. 1997 Sep;118(1):165-9
pubmed: 9243818
J Biol Chem. 2000 Mar 17;275(11):8027-31
pubmed: 10713122
Sci Rep. 2016 Jun 15;6:28010
pubmed: 27302574
Cancer Res. 2009 Jul 15;69(14):5627-9
pubmed: 19584271
J Clin Oncol. 2012 Feb 10;30(5):525-32
pubmed: 22253462
J Exp Clin Cancer Res. 2022 Jan 8;41(1):15
pubmed: 34998404
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S436-42
pubmed: 24566861
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Nat Methods. 2015 Jul;12(7):685-91
pubmed: 25984697
Cell. 2014 Sep 25;159(1):176-187
pubmed: 25201530
Nat Protoc. 2018 Jan;13(1):34-58
pubmed: 29215634
Cancer Res. 2000 Mar 15;60(6):1541-5
pubmed: 10749120
Transl Lung Cancer Res. 2020 Oct;9(5):1795-1809
pubmed: 33209602
Biochim Biophys Acta Rev Cancer. 2023 Mar;1878(2):188863
pubmed: 36796527
Breast Cancer Res Treat. 2020 Jun;181(3):571-580
pubmed: 32378053
Cancer Res. 2015 Mar 1;75(5):892-901
pubmed: 25592149
Anticancer Res. 2011 Feb;31(2):427-41
pubmed: 21378321
Mol Cancer. 2021 Mar 31;20(1):59
pubmed: 33789677
Nat Rev Cancer. 2014 Sep;14(9):623-31
pubmed: 25154812
PLoS One. 2017 Jun 6;12(6):e0173593
pubmed: 28586395
J Ovarian Res. 2018 Feb 26;11(1):16
pubmed: 29482638
ACS Omega. 2019 Dec 02;4(25):20882-20893
pubmed: 31867478
PLoS One. 2011;6(10):e26125
pubmed: 22022533
J Nanobiotechnology. 2011 Jul 29;9:29
pubmed: 21801388
Cancers (Basel). 2021 Jun 01;13(11):
pubmed: 34206049
Cell Stress. 2019 May 21;3(6):165-180
pubmed: 31225512
Oncogene. 2001 May 28;20(24):3021-7
pubmed: 11420717
Sci Rep. 2014 May 30;4:5122
pubmed: 24874299
Trends Cancer. 2015 Sep;1(1):44-52
pubmed: 28741562
J Biol Chem. 2002 Aug 2;277(31):27975-81
pubmed: 12032158
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9891-6
pubmed: 16788066
Cancers (Basel). 2020 Apr 07;12(4):
pubmed: 32272669
Eur J Cancer. 2019 Aug;117:60-68
pubmed: 31254940
Mol Cell Biol. 2001 Jun;21(12):3995-4004
pubmed: 11359907
Cell. 2019 Jan 10;176(1-2):98-112.e14
pubmed: 30633912
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Nat Cell Biol. 2001 Mar;3(3):245-52
pubmed: 11231573
Nature. 2019 Feb;566(7745):553-557
pubmed: 30728496
Cytometry A. 2018 Dec;93(12):1251-1254
pubmed: 30080307
Am J Pathol. 2007 Aug;171(2):386-95
pubmed: 17600130
Nat Commun. 2018 Aug 16;9(1):3279
pubmed: 30115931
Sci Rep. 2013;3:1124
pubmed: 23350031
Sci Transl Med. 2013 Apr 10;5(180):180ra48
pubmed: 23576814
Cell Rep. 2020 Sep 8;32(10):108105
pubmed: 32905777
BMC Cancer. 2012 May 16;12:178
pubmed: 22591372
Pathogens. 2022 May 18;11(5):
pubmed: 35631117
Theranostics. 2015 Jan 01;5(1):12-22
pubmed: 25553095
Mol Oncol. 2016 Mar;10(3):395-407
pubmed: 26795350
Int J Cancer. 2006 May 15;118(10):2609-16
pubmed: 16381002
J Biol Chem. 2004 Sep 24;279(39):40337-44
pubmed: 15271983
Lab Chip. 2014 Jan 7;14(1):89-98
pubmed: 24220648
Oncotarget. 2020 Mar 10;11(10):924-941
pubmed: 32206189
J Cell Physiol. 2020 Apr;235(4):3626-3633
pubmed: 31584203
Oncotarget. 2016 Sep 13;7(37):60101-60109
pubmed: 27517751
PLoS One. 2019 Sep 25;14(9):e0221305
pubmed: 31553731
Science. 2014 Jul 11;345(6193):216-20
pubmed: 25013076
Nat Med. 2011 Apr;17(4):500-3
pubmed: 21460848
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12486-91
pubmed: 25114222
Biometals. 2015 Feb;28(1):175-85
pubmed: 25511110
Oncotarget. 2016 Nov 1;7(44):71223-71234
pubmed: 27655722
Breast Cancer Res Treat. 2010 Nov;124(2):403-12
pubmed: 20859679
FASEB J. 2002 May;16(7):745-7
pubmed: 11923216
Sci Rep. 2018 Sep 5;8(1):13269
pubmed: 30185875
Cancers (Basel). 2019 Jul 24;11(8):
pubmed: 31344798
Nature. 1997 Jul 31;388(6641):482-8
pubmed: 9242408
Blood. 1993 Dec 15;82(12):3610-5
pubmed: 8260699
Lung Cancer. 2019 Aug;134:187-193
pubmed: 31319980
Breast Cancer Res. 2019 Jan 22;21(1):10
pubmed: 30670058
Nat Commun. 2020 Dec 9;11(1):6311
pubmed: 33298946
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7
pubmed: 20930119
Bioessays. 1998 Jan;20(1):41-8
pubmed: 9504046
Sci Transl Med. 2013 Apr 3;5(179):179ra47
pubmed: 23552373
FASEB J. 2005 Aug;19(10):1308-10
pubmed: 15941769
J Oncol. 2010;2010:617421
pubmed: 20016752
Cell Cycle. 2011 Apr 15;10(8):1249-60
pubmed: 21412054